
|Videos|January 26, 2022
Assessing the Future of Inclisiran in Clinical, Pharmacy Settings
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.
During the interview, Lepor discussed projections for the use of inclisiran in clinical and pharmacy settings.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
Dosing, Monitoring, and Counseling: The Pharmacist's Role in TKI Therapy for Systemic Mastocytosis
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
5





































































































